SCHEMBL6289615

SCHEMBL6289615

Cc1ccc(-c2c(OCCOc3ccccc3)nn(C)c2N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
POLB P06746 2/20 0.41
HPGD P15428 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
DRD2 P14416 3/20 0.40
DRD4 P21917 3/20 0.40
DRD3 P35462 3/20 0.40
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37
KCNA5 P22460 1/20 0.37
AR P10275 1/20 0.37
DHFR P00374 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6288927 0.88 MAPK14 (0.45) MAPTSMN1; SMN2RAB9ANPC1HPGD
SCHEMBL6288971 0.85 MAPT (0.41) MAPTRAB9ANPC1POLBTP53
SCHEMBL6292692 0.83 MAPT (0.39) MAPTSMN1; SMN2RAB9APOLBHPGD
SCHEMBL6361331 0.80 FABP4 (0.43) MAPT
SCHEMBL6292817 0.80 LMNA (0.37) MAPTSMN1; SMN2RAB9AHPGD
SCHEMBL13860530 0.76 MAPT (0.57) MAPTSMN1; SMN2RAB9ANPC1POLB
SCHEMBL13974933 0.71 MAPT (0.62) MAPTSMN1; SMN2RAB9ANPC1POLB
SCHEMBL1374376 0.70 DRD2 (0.69) MAPTRAB9ANPC1HPGDNPSR1
SCHEMBL6289740 0.69 POLB (0.49) MAPTSMN1; SMN2NPC1POLBHPGD
SCHEMBL6289612 0.67 MAPT (0.50) MAPTSMN1; SMN2RAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962923-B2 Pyrazole compositions PFIZER INC. (US) 2005-11-08 US disclosed
US-20030232848-A1 Pyrazole compositions PFIZER INC. 2003-12-18 US disclosed
US-6573270-B1 Endothelin receptor antagonists PFIZER INC. 2003-06-03 US disclosed
EP-1072597-A1 Pyrazoles and their use as endothelin antagonists Pfizer Limited (GB) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232848-A1 Pyrazole compositions EDNRB, EDNRA, AGTR1 MAPT 4430/4885SMN1; SMN2 4627/4885RAB9A 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.